British Journal of Cancer · 2003 · 116 citations · 42 references
MedicineGeriatric MedicineOncologyMedical OncologyPalliative CarePalliative MedicineCommunication With PatientsMetastatic Cancer ManagementPalliative Care For CancerPalliative Care In Older AdultsPalliative ChemotherapySupportive Care In CancerPalliative Care DecisionsPalliative Care In OncologyPalliative TherapySupportive Cancer CareTreatment Choice PreferencesTreatment Decision-making CommunicationTreatment Decision-making SupportTreatment Preference Discussions
In palliative cancer treatment, the choice between palliative chemotherapy and best supportive care may be difficult. In the decision-making process, giving information as well as patients' values and preferences become important issues. Patients, however, may have a treatment preference before they even meet their medical oncologist. An insight into the patient's decision-making process can support clinicians having to inform their patients. Patients (n=207) with metastatic cancer, aged 18 years or older, able to speak Dutch, for whom palliative chemotherapy was a treatment option, were eligible for the study. We assessed the following before they consulted their medical oncologist: (1) socio-demographic characteristics, (2) disease-related variables, (3) quality-of-life indices, (4) attitudes and (5) preferences for treatment, information and participation in decision-making. The actual treatment decision, assessed after it had been made, was the main study outcome. Of 207 eligible patients, 140 patients (68%) participated in the study. At baseline, 68% preferred to undergo chemotherapy rather than wait watchfully. Eventually, 78% chose chemotherapy. Treatment preference (odds ratio (OR)=10.3, confidence interval (CI) 2.8-38.0) and a deferring style of decision-making (OR=4.9, CI 1.4-17.2) best predicted the actual treatment choice. Treatment preference (total explained variance=38.2%) was predicted, in turn, by patients' striving for length of life (29.5%), less striving for quality of life (6.1%) and experienced control over the cause of disease (2.6%). Patients' actual treatment choice was most strongly predicted by their preconsultation treatment preference. Since treatment preference is positively explained by striving for length of life, and negatively by striving for quality of life, it is questionable whether the purpose of palliative treatment is made clear. This, paradoxically, emphasises the need for further attention to the process of information giving and shared decision-making.
42
The clinical evaluation of chemotherapeutic agents in cancer
David A. Karnofsky · Medical Entomology and Zoology · 1949 · 2.9K citations
Medicine, Oncology, Pharmacology +14
On the Elicitation of Preferences for Alternative Therapies
Barbara J. McNeil, Stephen G. Pauker, Harold C. Sox et al. · New England Journal of Medicine · 1982 · 1.7K citations
Peter Singer, Douglas K. Martin, Merrijoy Kelner · JAMA · 1999 · 1.3K citations
Information and Participation Preferences Among Cancer Patients
Barrie R. Cassileth · Annals of Internal Medicine · 1980 · 1.1K citations
Medicine, Health Behavior, Oncology +17